In The News - Volume 1 - Issue 18 - November 15, 2015

Seaweed may reduce tissue damage in organ transplants
Scientists are searching for promising new drugs in the most unusual of places, from the depths of the ocean floor to the contents of an infant’s nappy.
The goal is to discover substances that have a useful biological effect, for example new kinds of antibiotics, heart medicines and anti-cancer agents.
Dr Sharee Basdeo is involved in this research and is part of a group that discovered a possible new drug in ordinary seaweed to help reduce tissue damage caused by a transplant operation.
She is a research scientist in the school of biochemistry and immunology at Trinity College Dublin and is funded by Science Foundation Ireland.
Nov 10/15

Legalized uterus transplantation from deceased donors
France will become the first country in the world to authorize uterus transplants from deceased donors. This will give those who have birth defects or who have undergone surgical removal of the uterus a chance of finally becoming a mother. The Agence Nationale de Sécurité du Médicament (ASNM) announced that the groundbreaking operation will be carried out for the first time in a Limoges hospital by the end of 2016. The choice of brain-dead donors reflects the desire to avoid invasive surgery and surgical complications in living donors.
Nov 10/15

Liver Transplant: Ribavirin Not Necessary to Prevent HCV Recurrence
Patients with hepatitis C infection aren’t out of danger from the virus even after a successful liver transplant. But because they immune-compromised due to taking anti-rejection drugs, treatment is tricky. Reporting at the Liver Meeting in San Francisco, CA, Molly Hassett, MD of Vanderbilt University Nashville, TN, and colleagues reported on drug regimens for these patients.
They looked at whether these patients could safely eliminate ribavirin (RBV) from their drug regimens. They found they could.
Patients who had recurrent HCV infection after a transplant got 12 weeks of therapy with either simeprevir/sofosbuvir or ledipasvir/sofosbuvir without ribavirin.
Nov 14/15

US hospital to offer infertile women uterine transplants
Cleveland Clinic will offer transplants to 10 patients using a technique which has been successful in Sweden
A leading US hospital said on Thursday it is preparing to offer women uterine transplants, a technology that has been proven in Sweden and could help those struggling with infertility.
The Cleveland Clinic said it will be the first hospital in the United States to offer transplanted uteruses to 10 women beginning in the next few months.
Nov 13/15

Hansa Medical: Data Shows That One Dose of IdeS Has Favorable Effect and Completely Removes HLA-Antibodies
Hansa Medical AB (STO:HMED)
At Hansa Medical’s Capital Markets Day in Stockholm today, one of the world’s leading transplantation experts, Professor Stanley Jordan at Cedars-Sinai Medical Center, Los Angeles, will show data from one of his ongoing studies where highly sensitized patients are desensitized and treated with Hansa Medical’s lead candidate drug IdeS prior to transplantation.
Nov 13/15

Fortis to test drones to transport organs for transplantation
With the frequent traffic congestions in major cities and various other infrastructure related issues challenging the timely delivery of medical care, the healthcare service provider Fortis Healthcare is contemplating use of drones in medical care. The prominent use of drone is currently being discussed in transporting organs, especially for heart transplant within the city.
Fortis Healthcare, one of the healthcare major in the country, is testing the waters for active use of drones in organ transplants. With the technology improving, there are chances for increased number of organ transplant and creating a green corridor through the busy roads of the city.
Nov 15/15

Liver Transplant Lists Grow Shorter
Ever since direct-acting antivirals for hepatitis C came on the scene in 2013, physicians have been watching to see if the need for liver transplants will diminish. Reporting at the Liver Meeting in San Francisco, CA, Ryan Perumpail, MD, of Stanford University Medical Center in Pala Alto, CA said an analysis of recent United Network for Organ Sharing data shows that is happening. “The proportion of all new wait-list registrations for liver transplant represented by HCV patients declined from 34.8% in August 2012 to 26.8% in March 2015," he wrote.
Nov 14/15